Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10931)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22241)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5650)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (641)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22264)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma
    Meeting Abstract

    Aggen, D. H.; Garcia, A.; Saro Suarez, J. M.; Sauer, A.; Cristiani, S.; Brophy, F. E.; Streets, S.; Norry, E.; Nelson, A. A.; Kilari, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma
    Meeting Abstract

    Iyer, G.; Gao, X.; Rasco, D. W.; Milowsky, M. I.; Garmezy, B.; Rivera, I. I. R.; Tepper, J.; Moles, M. A.; Gjini, E.; Bowden, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study
    Meeting Abstract

    Van der Heijden, M. S.; Powles, T.; Gupta, S.; Bedke, J.; Kikuchi, E.; De Wit, R.; Galsky, M. D.; Duran, I.; Necchi, A.; Retz, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation
    Meeting Abstract

    Apolo, A. B.; Ballman, K. V.; Sonpavde, G. P.; Berg, S. A.; Kim, W. Y.; Parikh, R. A.; Teo, M. Y.; Sweis, R. F.; Geynisman, D. M.; Grivas, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)
    Meeting Abstract

    Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
    Meeting Abstract

    Iyer, G.; Palma, N. A.; Navarro, W. H.; Kwiatkowski, D. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save